NextCell Pharma AB Sustainability Reports
NextCell Pharma AB develops pioneering stem cell therapies focusing on its proprietary drug candidate, ProTrans, for the treatment of type 1 diabetes and other autoimmune and inflammatory diseases. The company also operates Cellaviva, Scandinavia's largest family preservation stem cell bank, and provides analytical services via QVance.
Sector: Professional & technical services
Country: Sweden
Exchange: Nasdaq Stockholm
LEI: 549300PBFGB5JYKXGA45
FIGI: BBG00GQQ3RZ7
5 reports from 2020 to 2023
